Navigation Links
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
Date:6/13/2013

Modified Human Growth Hormone (MOD-4023): Results of a Phase 2 Dose and Frequency Finding Study.  See abstract for more information.

SAT-644:
Pre-clinical Characterization of MOD-4023, a Long-Acting Growth Hormone.  See abstract for more information.

SAT-647:  Highly Producing Fed-Batch Manufacturing Process of Long-Acting Human Growth Hormone (MOD-4023) in CHO Cells.  See abstract for more information.

SUN-637:  Development of a Population Pharmacokinetic and Pharmacodynamic Model Following a Phase II Study of MOD-4023 in Growth Hormone Deficient Adults.  See abstract for more information.

ENDO 2013 abstracts are available online at: https://endo.confex.com/endo/2013endo/webprogram/COP.html.

ENDO 2013, the 95th Annual Meeting & Expo of the Endocrine Society, is being held June 15-18, 2013, in San Francisco.  For more information, visit:  https://www.endocrine.org/meetings/endo-annual-meeting/endo-2013#/nav/.

About PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is developing a long-acting version of human growth hormone, which is
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. OPKO Health To Acquire PROLOR Biotech
4. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
5. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015  Ardelyx, Inc. ... focused on cardio-renal, gastrointestinal and metabolic diseases, today ... has joined the Company,s Board of Directors. Dr. ... board level experience, having built and led teams ... regulatory approval and into healthcare systems globally. ...
(Date:4/20/2015)... 20, 2015  Eli Lilly and Company (NYSE: ... targeted cancer therapies, reflecting Lilly,s diverse oncology pipeline, during ... 2015, held April 18-22 in Philadelphia ... Patients" is the theme of this year,s AACR meeting ... broadening its portfolio of therapies that accelerate the pace ...
(Date:4/20/2015)... DELHI , April 20, 2015 ... PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform - ... EST  -  Supramolecular Assembly of Antibody-drug ... Cytotoxic Payload - Presented on Sunday, Apr 19, 1:00 ... leader in supramolecular therapeutic program, today announced that the ...
(Date:4/20/2015)... BEIJING, April 20, 2015 Sinovac Biotech Ltd. ... China, today announced its unaudited financial results for the ... Fourth Quarter 2014 Financial Highlights(Compared to the ... $20.3 million, a decrease of 11.4% from $22.9 million ... the stockpiling of H5N1 pandemic influenza vaccine of $0.1 ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... Insmed Inc. (Nasdaq CM: INSM ... host a conference call on Wednesday, May 13th at ... the first quarter 2009. Insmed intends to issue ... opens on May 13th.To participate in the live conference ...
... - Fourth Quarter 2008 Revenue Increased 28.6% to $14.1 Million, with Net, ... - 2008 Revenues Increased 23.5% to $59.1 Million vs. 2007, ... 20.1%, - 2008 Net Income Increased 13.7% to $4.1 Million ... - 2008 Cash Flow from Operations was $5.9 million, , ...
... Akaza Research will be conducting a presentation and exhibiting OpenClinica at ... Colorado Convention Center in Denver, CO. , ... Denver, ... Exhibition of the Association of Clinical Research Professionals (ACRP) will include ...
Cached Biology Technology:Insmed to Host First Quarter 2009 Conference Call 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition 2
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group ... NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one ... feedback on their experience with the Wocket in multiple scenarios ... CVS, Whole Foods and other retailers, making both debit and ... Tuttle also says, "If the company meets their plans ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... have published a step by step plan to one-day end ... developing plants that produce their own fertilizer. , ... required to produce nitrogen fertilizers has pushed the world-wide cost ... says that while they are necessary for high yields, those ...
... LOVE YOU! A red splash on a toxic butterfly,s wing ... mimic the wing pattern of another toxic species in the area. ... DON,T EAT US! , Now several research teams that ... butterflies mimic each other,s red wing patterns through changes in the ...
... Irvine, Calif., July 21, 2011 For 150 years ... the best-known examples of this is how poisonous butterflies from ... in effect joining forces to warn predators, "Don,t eat us," ... international team of researchers led by Robert Reed, UC Irvine ...
Cached Biology News:An eye gene colors butterfly wings red 2UCI-led butterfly study sheds light on convergent evolution 2
... system, 220-240 V, is used for biolistic particle ... employs an adjustable helium pulse to sweep DNA-, ... inner wall of a small plastic cartridge directly ... for in situ, in vitro, in vivo, and ...
... Hybridization Wash Pack provides optimized blocking ... Preparation Quality Clarifier: Ready-to-use wash solutions ... SigmaScreen(tm) APS Coated Slides for Microarrays ... Hybridization Blocking Buffer: 1L • Microarray ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: